Clinical trial NCT01336959: Safety & Efficacy of BCT197 in Patients Undergoing Cardiac Surgery
Official title: A Two-part, Randomized, Double-blind, Placebo-controlled, Single Dose Study of BCT197 for the Prevention of Acute Kidney Injury (AKI) in Patients Undergoing Elective Cardiac Surgery With Cardiopulmonary Bypass (CPB)
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Acute Kidney Injury
Keywords: Acute Kidney Injury
Cardiopulmonary Bypass
CABG
Cardiac Surgery
Lead sponsor: Mereo BioPharma
Sponsor class: INDUSTRY
Collaborators: name: Novartis
First posted: 2011-04-18
Enrollment: 91
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will assess the safety and efficacy of BCT197 on acute kidney injury in patients undergoing cardiac surgery with cardiopulmonary bypass.


Eligibility criteria: Inclusion Criteria:

* Patients scheduled for elective cardiac surgery with CPB. Allowable procedures are CABG alone, aortic valve replacement or repair alone, mitral valve replacement or repair alone, CABG with aortic valve replacement or repair, and CABG with mitral valve replacement or repair. Patients with repeat surgery for any of the procedures can be included.
* Patients must weigh at least 50 kg to participate in the study, and must have a body mass index (BMI) 18 kg/m2
* Have an eGFR ≥ 30 and ≤ 60 mL/min/1.73 m2 to participate in Part A, or an eGFR \> 60 mL/min/1.73 m2 to participate in Part B. Upon completion of Part A, patients with eGFR ≥ 30 mL/min/1.73 m2 may participate in Part B, with dose administered as per the dosing table

Exclusion Criteria:

* left ventricular ejection fraction, in the last 6 months, ≥30%
* Active systemic infection or uncontrolled diabetes mellitus with a glucose ≥250 mg% at the screening assessment
* Pregnant or nursing (lactating) women,
* Female subjects must either:

have been surgically sterilized or hysterectomized at least 6 months prior to study participation, or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks prior to study participation. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow- up hormone level assessment is she considered not of child bearing potential, Surgical sterilization procedures or hysterectomy must be supported with clinical documentation made available to the sponsor and noted in the Relevant Medical History / Current Medical Conditions section of the CRF, OR be postmenopausal. Female subjects are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms). Female subjects 60 years of age or younger must confirm menopause by the demonstration of a plasma FSH level in the postmenopausal range according to the lab normal range. Documentation of a prior plasma FSH level is acceptable

* History of drug or alcohol abuse within the 12 months prior to dosing, or evidence of drug abuse as indicated by the laboratory assays conducted during screening or baseline
* New cancer diagnosis with planned chemotherapy and/or radiation therapy, or cancer requiring ongoing chemotherapy and/or radiation therapy at the time of screening

Other protocol-defined inclusion/exclusion criteria may apply

Primary outcomes:
measure: Renal Function Measured at 48 Hours Post Cardiac Surgery With Cardiopulmonary Bypass Pump.
timeFrame: 48 hours
Secondary outcomes:
measure: Pharmacokinetic Measurements of Drug in Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass Pump. Pharmacokinetics Will be Measured Using Cmax
timeFrame: 4 days
Other outcomes:
Locations:
city: Orange
country: United States
facility: Novartis Investigative Site
state: California
city: Saginaw
country: United States
facility: Novartis Investigative Site
state: Michigan
city: Lincoln
country: United States
facility: Novartis Investigative Site
state: Nebraska
city: Cleveland
country: United States
facility: Novartis Investigative Site
state: Ohio
city: Wynnewood
country: United States
facility: Novartis Investigative Site
state: Pennsylvania
city: Falls Church
country: United States
facility: Novartis Investigative Site
state: Virginia
city: Be'er Sheva
country: Israel
facility: Novartis Investigative Site
city: Herzliya
country: Israel
facility: Novartis Investigative Site
city: Jerusalem
country: Israel
facility: Novartis Investigative Site
city: Petach Tikva
country: Israel
facility: Novartis Investigative Site
city: Rehovot
country: Israel
facility: Novartis Investigative Site
city: Tel-Aviv
country: Israel
facility: Novartis Investigative Site
city: Taipei
country: Taiwan
facility: Novartis Investigative Site
Study officials:
affiliation: Mereo BioPharma
name: Jacqueline Parkin, PhD FRCP
role: STUDY_DIRECTOR
References: